ASH 45th (2003)

Title Content type
Phase II Study of Denileukin Diftitox (Ontak) for Treatment of Steroid Resistant Acute Graft Versus Host Disease . Session Type: Poster Session 817-II (click for details)
Prophylactic Alternate Day Ganciclovir/Foscarnet (Gan/Fos) in at Risk Pediatric Allogeneic Stem Cell Transplant (AlloSCT) Recipients for Cytomegalovirus Is Effective in Preventing CMV Disease. Session Type: Publication Only (click for details)
Oral Voriconazole for Prophylaxis of Fungal Infections during Allogeneic Hematopoietic Stem Cell Transplantation in Patients at Risk. Session Type: Publication Only (click for details)
Continuous Complete Remission (CR) Following Reduced-Intensity Stem Cell Transplantation (RIST) Using Fludarabine and Busulfan with or without Total Body Irradiation in Patients with Refractory Peripheral T-Cell Lymphomas (PTCL), Unspecified. Session Type (click for details)
Elimination of Aspergillus as a Significant Pathogen in an Allogeneic Hematopoietic Stem Cell Transplant Program after Introduction of Routine Long-Term Itraconazole Prophylaxis. Session Type: Oral Session (click for details)
Non-Myeloablative Umbilical Cord Blood Transplantation in 40 High-Risk Adults: Extending Access to Transplant with High Rate of Engraftment, Low Risk of Severe Acute GVHD and Demonstration of Graft-versus-Malignancy Effect. Session Type: Oral Session (click for details)
Clinical Impact of Hyperacute Graft-Versus-Host Disease on the Results of Allogeneic Stem Cell Transplantion. Session Type: Publication Only (click for details)
Real Time Quantitative PCR: Empirical Studies on Fungal Diagnostics. Session Type: Publication Only (click for details)
Low-Dose (50 mg) Alemtuzumab (Campath) in Myeloablative Allogeneic Stem Cell Transplantation for CD52+ Aggressive Hematological Malignancies: Decreased Incidence of Acute Graft-Versus-Host Disease (aGVHD), with Unique Pharmacokinetics. Session Type: Poste (click for details)
Immunotherapy for Resistant Hematologic Malignancies Using Matched or Mismatched rIL-2 Activated Donor Lymphocytes Positively Selected for CD56+ after Allogeneic Stem Cell Transplantation for Allogeneic Cell Therapy without GVHD. Session Type: Publication (click for details)

Pages

Subscribe to ASH 45th (2003)